# To Study the Pathophysiological Features of Multiple Sclerosis

> **NCT04242056** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chang Gung Memorial Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Multiple Sclerosis
- Neurofilament Light Chain
- Glial Fibrillary Acidic Protein

## Interventions

- **DRUG:** 18F-PM-PBB3

## Key facts

- **NCT ID:** NCT04242056
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-20
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04242056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04242056, "To Study the Pathophysiological Features of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04242056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*